Neuroscience: The Second Growth EngineNarrow moat

AbbVie (ABBV) — moat facet

AbbVie's neuroscience drugs, mostly bought with Allergan, sell $10.8 billion a year and are growing 20%.

AbbVie's neuroscience business has quietly become its second engine. It sold $10,767 million in 2025, up from $7,717 million in 20231, and $3,228 million in the second quarter of 2026, up 20.3%2. Management assumed about $12.5 billion for 20263.

Neuroscience sales, 2025 ($M)Botox Therapeutic3,769Vraylar3,621Ubrelvy1,271Qulipta1,036Vyalev482AbbVie Form 10-K FY2025
Five products carry it.

The portfolio is broad. Vraylar, for schizophrenia and bipolar disorder, sold $3,621 million in 2025; Botox Therapeutic $3,769 million; the migraine drugs Ubrelvy and Qulipta $1,271 million and $1,036 million; and Vyalev, for Parkinson's disease, $482 million in its first full year of meaningful sales4.

Much of it came with Allergan: Vraylar, Botox and the migraine drugs were Allergan products. The acquisition that critics called overpriced delivered the business now growing fastest after immunology.

The risks are the usual ones for this collection: government prices for Vraylar from 2027 and Botox from 20285, and generic challenges to Ubrelvy and Qulipta already filed by several generic makers6.

The line's growth has been steady for years. Neuroscience sold $6,528 million in 2022, $7,717 million in 2023 and $8,999 million in 2024 before $10,767 million in 20257. Each of its main drugs grew in 2025: Vraylar, Botox Therapeutic, Ubrelvy, Qulipta and Vyalev8.

Neuroscience is a genuine second leg. Its growth rate is the figure to follow, 20.3% in the second quarter of 2026; holding above 10% through the Vraylar price cut in 2027 would say the business can grow through government pricing.

Moat trajectory: Widening

Grew 20.3% in Q2 2026.

The number that tests this moat
Reported
Neuroscience revenue, latest quarter
$3,228M, +20.3% (Q2 2026)

The second engine; growth above 10% through Vraylar's 2027 government price would show it can grow through price cuts.

Source: AbbVie Q2 2026 results release ↗
⚠ Threats to the moat
⚠ THREAT 01
Cerevel's $4.5 Billion Write-Off
AbbVie wrote off $4.5 billion of the $8.7 billion Cerevel purchase within months, when its lead schizophrenia drug failed.
References
  1. ReportedIt sold $10,767 million in 2025, up from $7,717 million in 2023, and $3,228 million in the second quarter of 2026, up 20.3%.
    AbbVie Form 10-K for fiscal 2025 - Item 1 business: products, customers, competition and research. — FY2025 · publ. 20 February 2026 · source ↗
  2. ReportedIt sold $10,767 million in 2025, up from $7,717 million in 2023, and $3,228 million in the second quarter of 2026, up 20.3%.
    AbbVie second-quarter 2026 results release, Form 8-K exhibit 99.1. — Q2 2026 · publ. 31 July 2026 · source ↗
  3. ReportedManagement assumed about $12.5 billion for 2026.
    The Motley Fool, AbbVie Q4 2025 earnings call transcript - 2026 revenue assumptions by product and management's comments on share and competitors. — Q4 2025 · publ. 4 February 2026 · source ↗
  4. ReportedVraylar, for schizophrenia and bipolar disorder, sold $3,621 million in 2025; Botox Therapeutic $3,769 million; the migraine drugs Ubrelvy and Qulipta $1,271 million and $1,036 million; and Vyalev, for Parkinson's disease, $482 million in its first full year of meaningful sales.
    AbbVie Form 10-K for fiscal 2025 - Item 7 MD&A: net revenues by product and region, and rebates. — FY2025 · publ. 20 February 2026 · source ↗
  5. ReportedThe risks are the usual ones for this collection: government prices for Vraylar from 2027 and Botox from 2028, and generic challenges to Ubrelvy and Qulipta already filed by several generic makers.
    AbbVie Form 10-K for fiscal 2025 - Item 1A risk factors, patents and exclusivity, government pricing and legal proceedings. — FY2025 · publ. 20 February 2026 · source ↗
  6. ReportedThe risks are the usual ones for this collection: government prices for Vraylar from 2027 and Botox from 2028, and generic challenges to Ubrelvy and Qulipta already filed by several generic makers.
    AbbVie Form 10-Q for the quarter ended 30 June 2026 - product revenue, the balance sheet, cash flow and the Apogee agreement. — Q2 2026 · publ. 3 August 2026 · source ↗
  7. Moat Explorer calcNeuroscience sold $6,528 million in 2022, $7,717 million in 2023 and $8,999 million in 2024 before $10,767 million in 2025.
    Moat Explorer calculation from AbbVie's reported product revenue and financial statements ($ millions unless stated). Therapeutic areas 2025: immunology 17,562 + 8,304 + 4,540 = 30,406; neuroscience 3,621 + 3,769 + 1,271 + 1,036 + 482 + 381 + 207 = 10,767; oncology 2,869 + 2,792 + 690 + 271 + 33 = 6,655; aesthetics 2,602 + 993 + 1,265 = 4,860; eye care 493 + 410 + 197 + 1,009 = 2,109; other key products 1,317 + 1,512 + 907 = 3,736; all other 2,627; eye care and other products 2,109 + 3,736 + 2,627 = 8,472; total 61,160. 2024: immunology 11,718 + 5,971 + 8,993 = 26,682; neuroscience 8,999; oncology 6,555; aesthetics 5,176; eye care and other 2,242 + 3,648 + 3,032 = 8,922. 2023: 7,763 + 3,969 + 14,404 = 26,136; neuroscience 7,717; oncology 5,915; aesthetics 5,294; eye care and other 2,415 + 3,806 + 3,035 = 9,256. 2022: 5,165 + 2,522 + 21,237 = 28,924; neuroscience 6,528; oncology 6,577; aesthetics 5,333; eye care and other 2,701 + 3,854 + 4,137 = 10,692. Growth 2025: immunology 30,406 / 26,682 - 1 = 14.0%; neuroscience 10,767 / 8,999 - 1 = 19.6%. Immunology and neuroscience 30,406 + 10,767 = 41,173, 41,173 / 61,160 = 67.3%. Immunology share 30,406 / 61,160 = 49.7%. Skyrizi + Rinvoq: 5,165 + 2,522 = 7,687 (2022); 7,763 + 3,969 = 11,732 (2023); 11,718 + 5,971 = 17,689 (2024); 17,562 + 8,304 = 25,866 (2025); H1 2026 9,988 + 4,644 = 14,632; Q2 2026 5,505 + 2,525 = 8,030, 8,030 / 16,990 = 47.3%; 2026 plan 21.5 + 10.1 = 31.6 bn. Shares of revenue 7,687 / 58,054 = 13.2%; 11,732 / 54,318 = 21.6%; 17,689 / 56,334 = 31.4%; 25,866 / 61,160 = 42.3%. Humira: 4,540 / 21,237 - 1 = -78.6%; share 8,993 / 56,334 = 16.0% (2024), 4,540 / 61,160 = 7.4% (2025). Rebates: 65.1 / 61.16 = 1.06; 65.1 / 18.8 = 3.5 times (2019-2025) against net revenues 61,160 / 33,266 = 1.8 times; gross sales 61.2 + 65.1 = 126.3 bn, 126.3 / 61.2 = 2.1 times; managed care 22,307 / 61,160 = 36.5%; Medicaid and Medicare 21,283 / 61,160 = 34.8%; payers 22,307 + 21,283 = 43,590, 43,590 / 61,160 = 71.3%. Geography: US 46,603 / 61,160 = 76.2%; international 14,557 / 61,160 = 23.8%. Gross margin 2025 (61,160 - 18,204) / 61,160 = 70.2%. Government-set price products, 2025 sales: 2,869 + 3,621 + 907 + 3,769 = 11,166, 11,166 / 61,160 = 18.3%. Goodwill and intangibles 35,640 + 52,641 = 88,281, 88,281 / 133,960 = 65.9%. Eye care share 2,109 / 61,160 = 3.4%; aesthetics share 4,860 / 61,160 = 7.9%. Net debt 30 June 2026: 62,481 + 8,341 - 6,569 = 64,253; net debt / operating cash flow 64,253 / 19,030 = 3.4 years. Free cash flow 2025: 19,030 - 1,214 = 17,816; dividends paid 11,657 / 17,816 = 65.4%; operating cash flow / dividends 19,030 / 11,657 = 1.6; dividends declared / net earnings 11,819 / 4,226 = 2.8; dividends per share 6.65 / 1.75 = 3.8 times (2014-2025). Free cash flow yield 17,816 / 468,500 = 3.8%; free cash flow per share 17,816 / 1,771 = 10.06. 2026 adjusted EPS guidance midpoints: (14.37 + 14.57) / 2 = 14.47; (13.96 + 14.16) / 2 = 14.06; (14.08 + 14.28) / 2 = 14.18; (13.91 + 14.11) / 2 = 14.01; (13.87 + 14.07) / 2 = 13.97. Ubrelvy and Qulipta Q2 2026 392 + 350 = 742; 2025 1,271 + 1,036 = 2,307. Skyrizi share 17,562 / 61,160 = 28.7%. Juvederm 993 / 1,428 - 1 = -30.5%. Aesthetics 4,860 / 5,176 - 1 = -6.1%. Gross margin 2023 (54,318 - 20,415) / 54,318 = 62.4%. Skyrizi + Rinvoq 2021 2,939 + 1,651 = 4,590; 2022 7,687 / 21,237 = 36% - therapeutic-area totals, growth and rebates. — 2015-2026 · publ. September 2026 · source ↗
    Method: Arithmetic on figures reported in AbbVie's Forms 10-K, 10-Q, results releases, the Q4 2025 call and market data; operands shown in the source line.
  8. ReportedEach of its main drugs grew in 2025: Vraylar, Botox Therapeutic, Ubrelvy, Qulipta and Vyalev.
    AbbVie Form 10-K for fiscal 2025 - Item 7 MD&A: net revenues by product and region, and rebates. — FY2025 · publ. 20 February 2026 · source ↗
Sources
Generated September 25, 2026